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Objectives To provide a comprehensive assessment of case stratification by the Neonatal Early-Onset Sepsis
(EOS) Calculator, a novel tool for reducing unnecessary antibiotic treatment.
Study design A systematic reviewwith individual patient datameta-analysis was conducted, extending PROSPERO
record CRD42018116188. Cochrane, PubMed/MEDLINE, EMBASE, Web of Science, Google Scholar, and major con-
ferenceproceedingswere searched from2011 throughMay1, 2020.Original data studies including culture-provenEOS
case(s) with EOS Calculator application, independent from EOS Calculator development, and including representative
birth cohorts were included. Relevant (individual patient) data were extracted from full-text and data queries. The main
outcomes were the proportions of EOS cases assigned to risk categories by the EOS Calculator at initial assessment
and within 12 hours. Evidence quality was assessed using Newcastle-Ottawa scale, Critical Appraisal and Data Extrac-
tion for Systematic Reviews of Prediction Modelling Studies, and GRADE tools.
Results Among 543 unique search results, 18 were included, totaling more than 459 000 newborns. Among 234
EOS cases, EOS Calculator application resulted in initial assignments to (strong consideration of) empiric antibiotic
administration for 95 (40.6%; 95% CI, 34.2%-47.2%), more frequent vital signs for 36 (15.4%; 95% CI, 11.0%-
20.7%), and routine care for 103 (44.0%; 95% CI, 37.6%-50.6%). By 12 hours of age, these proportions changed
to 143 (61.1%; 95% CI, 54.5%-67.4%), 26 (11.1%; 95% CI, 7.4%-15.9%), and 65 (27.8%; 95% CI, 22.1%-34.0%)
of 234 EOS cases, respectively.
Conclusions EOS Calculator application assigns frequent vital signs or routine care to a substantial proportion of
EOS cases. Clinical vigilance remains essential for all newborns. (J Pediatr 2021;234:77-84).See related article, p 71linical practice in management of suspected early-onset sepsis (EOS) is widely being reevaluated, because of decliningC incidence and increasing recognition that use of empiric antibiotics can have adverse consequences.1,2 The NeonatalEarly-Onset Sepsis Calculator developed by Kaiser Permanente is a novel tool for allocating antibiotics to newborns
born at 34 or more weeks of gestation.3-5 It provides clinicians with individualized, quantitative risk estimates based on
maternal risk factors and objective neonatal clinical findings, along with recommendations for clinical management ranging
from routine care to administration of empiric antibiotics.6 A systematic review concluded that the implementation of theFrom the 1Department of Pediatrics, Tergooi Hospital,
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indicated noninferiority compared with conventional management, with a
similar proportions of culture-proven EOS cases receiving antibiotic therapy
within 24 hours after birth.
Potential delays in identification and treatment of culture-proven EOS are a
major concern regarding the EOS Calculator.8-11 The majority of 51 EOS cases
in the largest implementation study to date had an estimated EOS Calculator
risk below the threshold for empiric antibiotics at birth.12 Much smaller studies
have identified several more cases where the application of the EOS Calculator
did not lead to the recommendation of empiric antibiotic therapy.12-14 The
aim of this study was to provide clinicians with a comprehensive and represen-
tative overview of how culture-proven EOS cases are stratified into different risk
categories by the EOS Calculator. Because clinical monitoring using vital signs
is included in EOS Calculator recommendations, the secondary aim was tooutside the submitted work. E.G. is supported by the
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among those cases. The results provide important data
regarding implementation and direct future research, and
facilitate comparison with alternative strategies.
Methods
We performed a systematic review and individual patient
meta-analysis of EOS cases reported in the literature evalu-
ating the EOS Calculator, as detailed elsewhere in this article.
For this study, we extended our previous systematic review
analyzing the EOS Calculator,7 which was registered in
advance (CRD42018116188, PROSPERO database). We fol-
lowed the PRISMA-IPD methodology,15 described in detail
in the PRISMA-IPD protocol (Appendix 1; available at
www.jpeds.com). There was no funding source for this study.
Study Eligibility Criteria
We defined the study selection criteria as follows: studies re-
porting any original data on at least 1 culture-proven EOS
case with application of the EOS Calculator, independent
from EOSCalculator development, and including a represen-
tative birth cohort. Studies of preselected at-risk cohorts,
such as newborns exposed to chorioamnionitis or prolonged
rupture of membranes, those with clinical signs of illness, or
newborns selectively admitted to a particular unit or level of
care were excluded. This limitation was used to avoid over-
sampling of at-risk cases, which would distort overall assess-
ment of the EOS Calculator recommendations. An EOS case
was defined as a newborn with a positive blood or cerebrospi-
nal fluid culture within 72 hours after birth.
Information Sources and Search Strategy
A systematic search of the EOS Calculator literature in the
Cochrane, Embase, and PubMed/MEDLINE databases7
and review of articles citing original EOS Calculator publi-
cations identified through Google Scholar and/or Web of
Science search engines was updated to extend through
May 1, 2020 (see protocol, Appendix 1). Databases were
searched for equivalents of EOS Calculator in all fields.
We also searched for predictive, risk, quantitative, or
stratification, combined with model or algorithm, and
equivalents of EOS in titles and abstracts. Available
abstracts of large international conferences of pediatric
societies since 2014 (Pediatric Academic Societies,
American Academy of Pediatrics, European Society of
Pediatric Infectious Diseases, European Academy of
Paediatrics) were searched for sepsis and results were
screened manually for eligibility. Citations were combined
and duplicates excluded manually.
Study Selection and Data Collection
Publications not identified in the previous search were inde-
pendently assessed for eligibility by at least 2 authors.
Another author was consulted to resolve any disagreements.7
Because of updated study eligibility criteria, we reassessed78results previously excluded because of “no outcome data”
and “no peer-review” results using the same procedure.
For each study, 2 authors independently extracted data on
study location, study design, EOS Calculator implementation,
number of births in the base population, and number of EOS
cases. Individual patient data on maternal EOS Calculator
input variables (maternal group B Streptococcus colonization
status, duration of rupture of membranes, gestational age,
maximum maternal intrapartum temperature, and adminis-
tration and timing of intrapartum antibiotics), and clinical
classification of the newborn (well-appearing, equivocal, or
clinical illness) were extracted for each EOS case. The EOS
Calculator uses detailed objective criteria and cut-offs for these
classifications, with criteria including the (persistent) need for
respiratory support or vasoactive drugs, presence of seizures or
low Apgar scores, and/or the presence of persistent physiologic
abnormalities in heart rate, respiratory rate, respiratory
distress, and/or temperature instability.4-6 For each newborn
in this study, we used the clinical classification assigned by
the original authors when they applied the EOS Calculator.
The occurrence and onset of EOS symptoms and isolated
pathogen data were extracted when available. If data were
incomplete, corresponding authors were queried using a
standardized data collection form and/or single missing ele-
ments were inferred by application of the EOS Calculator to
reproduce reported risk estimates (eg, inferring exact gesta-
tional age by calculating that required to reproduce the orig-
inally reported EOS risk). Additional or updated data
revealed by author queries were included. For studies for
which individual patient data could not be obtained, aggre-
gate results on EOS Calculator recommendations were re-
viewed if available, but these subjects were not included in
the individual patient meta-analysis.
Risk of Bias Assessment
To assess risk of bias within studies, we used applicable items
from the Newcastle-Ottawa Scale for cohort studies, and the
Critical Appraisal and Data Extraction for Systematic Reviews
of Prediction Modelling Studies (CHARMS) checklist. To
assess risk of bias across studies and for the accumulated evi-
dence, we used the Grading of Recommendations Assessment,
Development, and Evaluation method.16,17 The risk of publi-
cation bias was not assessed separately, because the search
included non-peer-reviewed results and outcome data were
expected to be too rare to allow for a meaningful funnel plot.
Exclusion of Spurious or Transient Bacteremias
In cases in which cultures yielded potential nonpathogenic or
contaminant isolates (such as coagulase-negative Staphylo-
coccus), we deferred to the judgments of the original authors
regarding the diagnosis of EOS. EOS cases clearly resembling
transient bacteremia, defined as newborns with a positive
blood culture obtained solely because of maternal risk factors
who remained asymptomatic until discharge in the absence
of antibiotic therapy and/or had a sterile follow-up blood cul-
ture obtained before initiation of treatment were excluded,
with confirmation from the original authors.Achten et al
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For each EOS case, the recommendations of the EOS Calcu-
lator (blood culture and empiric antibiotic therapy, strong
consideration of empiric antibiotic treatment, blood culture
and frequent vital signs, frequent vital signs alone, or routine
care) were recalculated at the initial assessment (with exam-
ination), and separately including clinical signs over the first
12 hours. The proportions of EOS cases identified by the EOS
Calculator at the initial assessment and by 12 hours of age
were calculated, with exact 95% CIs (Clopper-Pearson
method).18 All data were analyzed using Excel (Microsoft)
and R, version 3.6.0 (R Foundation for Statistical
Computing).
The online EOS Calculator requires choice of a specific
EOS population baseline incidence. For consistency, we
used a homogenous incidence of 0.6 per 1000 live births,
closest to that in the development sample.19 The incidence
can be adjusted to tailor the tool to a specific population,543 unique results
22 eligible studies 










243 EOS cases included
9 transient bacteremia case
excluded
Figure 1. Flowchart of search results and study selection. AAP, A
PAS, Pediatric Academic Societies.
Stratification of Culture-Proven Early-Onset Sepsis Cases by the
Patient Data Meta-Analysisbut this requires prior calibration and/or validation.19 This
is analogous to altering the threshold for treatment in the
opposite direction (a higher incidence mimics a lower treat-
ment threshold), which can be a clinical decision.20 Addi-
tional analysis was performed to assess effects of different
treatment thresholds or population incidences (as offered
by the online EOS Calculator) on the proportion of EOS
cases assigned treatment.We also assessed whether the results
differed if the analysis was stratified by EOS pathogen or
restricted to prospective data and explored the relationship
between age at onset and EOS Calculator risk estimates.Results
Included Studies and EOS Cases
The updated literature search revealed a total of 543 unique
publications, of which 174 were selected for full-text review369 excluded based on title/abstract
343 non-Calculator








152 excluded after full-text review
32 non-Calculator
56 no original data
42 no EOS cases
8 updated data available
13 non-representative cohort
1 Calculator development study
252 excluded (duplicate results)
4 with IPD unavailable
1 unable to provide IPD in time
3 no reply from authors
2 studies with unknown number of 
EOS cases
1 study with 2 EOS cases but 
insufficient data
1 study with 5 EOS cases
s 
merican Academy of Pediatrics; IPD, Individual Patient Data;
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including 13 involving only nonrepresentative cohorts, and
8 because the same subjects were also described in
subsequent publications.
Four studies were excluded frommain analysis because in-
dividual patient data could not be obtained, leaving 18
studies for inclusion (Table I).12,13,21-41 Eleven were from
the US, 3 from the UK, and 4 from other countries.
Individual patient data were obtained for a total of 243
EOS cases, from birth cohorts including more than 459 113
births. Of these, 9 were considered cases of transient
bacteremia (Table II; available at www.jpeds.com), leaving
234 for analysis (Table III; available at www.jpeds.com).
Birth cohort size was known for 17 studies, with an overall
EOS incidence of 0.50 per 1000 live births. Among the 4
studies without individual patient data, 1 contained
relevant aggregate results on the main outcome, describing
5 EOS cases.23
Risk of Bias
Studies were classified as having a high risk of bias for 11, low
for 4, and unclear for 3 studies (Table IV; available at www.
jpeds.com). We graded the overall quality of the evidence for
the primary outcome as low, considering that data of 174 of
234 EOS cases (74.4%) were collected retrospectively. We
identified 2 EOS cases with imputed highest maternal
temperature (37.0C), but no other issues compromising
individual patient data integrity.13,25
Classification of EOS Cases by the EOS Calculator
At the initial assessment, the EOS Calculator application re-
sulted in recommendation of empiric antibiotic treatment or
strong consideration of treatment in 95 (40.6%; 95% CI,
34.2-47.2), frequent vital signs with or without blood cultures
for 36 (15.4%; 95% CI, 11.0-20.7%), and routine care for 103Table I. Included studies
Study Country Design
Achten et al25 2018 NL Retrospective + Prospective
Arora et al26 2019 US Retrospective + Prospective
Bajracharya et al27 2019 US Retrospective
Benaim et al28 2019 US Retrospective
Davidson et al29 2016 UK Prospective
Dhudasia et al30 2018 US Retrospective
Fischer et al31 2018 US Retrospective
Fowler et al32 2019 US Retrospective
Goel et al33 2020 UK Prospective
Hershkovich-Shporen et al34 2019 Israel Retrospective
Joshi et al35 2019 US Retrospective
Kopec et al36 2018 US Retrospective
Kuzniewicz12 US Prospective
Morris et al37 2017 UK Retrospective
Perez et al38 2019 US Prospective
Procianoy et al39 2019 Brazil Retrospective
Sharma et al40 2019 US Prospective
Strunk et al41 2018 Australia Prospective
Total
N/A, not available; NL, The Netherlands.
Gestational age is the threshold for subject inclusion.
80(44.0%; 95% CI, 37.6-50.6%) of 234 EOS cases (Figure 2 and
Table V). There were no instances of treatment initiation
because of a positive screening blood culture. After the
incorporation of examination findings over the first
12 hours after birth (in accordance with its intended use),
the EOS Calculator recommended antibiotic treatment or
strong consideration of treatment in 143 (61.1%; 95% CI,
54.5%-67.4%), frequent vital signs with or without blood
culture for 26 (11.1%; 95% CI, 7.4%-15.9%), and routine
care for 65 (27.8%; 95% CI, 22.1%-34.0%) cases (Table V).5
EOS case classification was similar when restricted to pro-
spectively collected data (Table VI; available at www.jpeds.
com). Finally, the study providing only aggregate results
indicated that the EOS Calculator identified 5 of 5 EOS
cases, but without indicating the population incidence
used.23
Effects of Adjusted Treatment Thresholds or
Incidence Rates
Using treatment thresholds ranging from 0.45 to 18.0 cases
per 1000 live births, which approximates use of population
incidence rates ranging from 0.1 to 4.0 per 1000 live births
(as offered in the online calculator), we found that lower
treatment thresholds (at a fixed population incidence) or
higher EOS incidence rates (at a constant treatment
threshold) would increase the proportion of cases for which
treatment is recommended (Table VII; available at www.
jpeds.com).
Recommendations in the Context of Pathogen and
Onset of Clinical Illness
Among included EOS cases for which the causative organism
was reported, group B Streptococcus was the most common
pathogen (116/228; 50.9%), followed by Escherichia coli
(37/228; 16.2%) (Table V). For the 153 cases caused byGestational age Birth cohort (n) EOS cases Implementation
³35 3953 4 Before/after
³34 N/A 5 Before/after
³34 2066 7 No
³34 1367 5 No
³34 1351 3 No
³36 11 782 4 Before/after
³35 8240 5 No
³34 6517 6 Before/after
³34 4992 6 No
³35 7058 6 No
³34 19 996 7 No
³34 25 688 49 No
³35 204 685 42 Before/after
³34 142 333 70 No
³35 2916 2 Yes
³34 8321 9 No
³36 5346 3 Before/after
³35 2502 1 Yes
>459 113 234
Achten et al
Figure 2. Pathways leading to treatment according to the EOS Calculator algorithm. Calculator recommendations at the initial
assessment. Numbers in bold italics represent the number of cases within the adjacent branch of the flow diagram. Risk esti-
mates expressed as cases per 1000 births. Infants with high initial risk estimates were much more likely to have clinical signs of
illness immediately after birth (P < .0001). *Clinical signs of illness developing after initial assessment. EGA, estimated gestational
age.
July 2021 ORIGINAL ARTICLESthese typical EOS pathogens, the EOS Calculator
recommended antibiotics for 54 patients (35.3%) at initial
assessment and for 82 patients (53.6%) within 12 hours
after birth. The initial recommendations across categories
did not vary significantly by causative organism (P = .13).
The EOS Calculator paradigm partly depends on clinical







Recommendation at initial assessment, n (% of group)
Group B Streptococcus† 116 (50.9) 36 (31.0)
E coli† 37 (16.2) 18 (47.1)
Viridans group streptococci 17 (7.5) 8 (47.1)
Coagulase-negative Staphylococcus 12 (5.3) 3 (25.0)
Enterococcus spp. 8 (3.5) 3 (37.5)
L monocytogenes 5 (2.2) 2 (40.0)
S aureus 5 (2.2) 0 (0.0)
Other 29 (12.7) 9 (30.0)
Total (known organisms) 228 (100.0) 78 (34.2)
All subjects 234 (100.0) 84 (35.9)
Recommendation in first 12 hours, n (% of group)
Group B Streptococcus† 116 (50.9) 60 (51.7)
Escherichia coli† 37 (16.2) 22 (59.5)
Viridans group streptococci 17 (7.5) 8 (47.1)
Coagulase-negative Staphylococcus 12 (5.3) 3 (25.0)
Enterococcus spp. 8 (3.5) 3 (37.5)
L monocytogenes 5 (2.2) 2 (40.0)
S aureus 5 (2.2) 1 (20.0)
Other 29 (12.7) 10 (33.3)
Total (known organisms) 228 (100.0) 108 (47.6)
All subjects 234 (100.0) 114 (48.7)
*Identities of the causative organisms were not available for one study (6 EOS cases).
†One case with group B Streptococcus and E coli dual infection is counted in data for both pathoge
Stratification of Culture-Proven Early-Onset Sepsis Cases by the
Patient Data Meta-Analysisdata (Figure 3; available at www.jpeds.com), 149 (82.8%)
exhibited clinical signs of illness at their initial assessment
(n = 63) or later (n = 86); of these, 120 cases (80.5%)
showed signs within 12 hours after birth, 133 (89.3%)
within 24 hours, and 146 (98.0%) within 48 hours. Among
the 104 cases with time of onset data who were neither











4 (3.4) 14 (12.1) 3 (2.6) 59 (50.9)
1 (2.7) 5 (13.5) 2 (5.4) 11 (29.7)
2 (11.8) 1 (5.9) 1 (5.9) 5 (29.4)
1 (8.3) 1 (8.3) 0 (0.0) 7 (58.3)
0 (0.0) 0 (0.0) 1 (12.5) 4 (50.0)
0 (0.0) 1 (20.0) 0 (0.0) 2 (40.0)
0 (0.0) 1 (20.0) 2 (40.0) 2 (40.0)
3 (13.3) 3 (10.0) 1 (3.3) 13 (43.3)
11 (4.8) 26 (11.4) 10 (4.4) 103 (45.2)
11 (4.7) 26 (11.1) 10 (4.3) 103 (44.0)
20 (17.2) 5 (4.3) 3 (2.6) 28 (24.1)
3 (8.1) 4 (10.8) 2 (5.4) 6 (16.2)
2 (11.8) 1 (5.9) 1 (5.9) 5 (29.4)
1 (8.3) 1 (8.3) 0 (0.0) 7 (58.3)
0 (0.0) 0 (0.0) 1 (12.5) 4 (50.0)
0 (0.0) 1 (20.0) 0 (0.0) 2 (40.0)
0 (0.0) 1 (20.0) 2 (40.0) 1 (20.0)
3 (13.3) 3 (10.0) 1 (3.3) 12 (40.0)
29 (12.7) 16 (7.0) 10 (4.4) 65 (28.4)
29 (12.4) 16 (6.8) 10 (4.3) 65 (27.8)
ns.
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24 hours of age in 64 patients (61.5%) and by 48 hours of
age in 80 patients (76.9%).
Thirty-one infants never had signs of illness. Two were
treated based on risk estimates provided by the EOS Calcu-
lator.30 For the other 29, the EOS Calculator (applied only
in retrospect) would have recommended treatment in 5,
blood culture for 5, frequent vital signs for 4, and routine
care in 15. For the 24 infants for whom treatment would
not have been recommended, it was given for maternal fever
or more than 38C (12 cases), rupture of membranes of more
than 24 hours (7), encephalocele (1), group B Streptococcus
colonization with no intrapartum prophylaxis (1), or
without specified cause (3).Discussion
With the association of the EOS Calculator with decreased
use of empiric antibiotics clearly established, the primary
question has become how well it performs in identifying
EOS cases.25 Using a consistent population risk estimate
(0.6 per 1000 live births), the EOS Calculator recommends
the administration of or strong consideration of antibiotics
in 40.6% of EOS cases at the initial assessment after birth,
increasing to 61.1% by 12 hours of age. Routine care was
initially recommended for 103 infants with EOS (44.0%).
The underlying prediction model performed better in the
original data, with administration of antibiotics strictly rec-
ommended in 61% of EOS cases within 12 hours after birth.4
Decreased performance of prediction models as they are im-
plemented in clinical practice is common and does not imply
lack of clinical utility. However, the initial assignment of
more than 40% of newborns ultimately diagnosed with
EOS to “routine care” indicates that vigilance is required
for all newborns, not merely those identified as at risk.
The EOS Calculator involves clinical monitoring beyond
the initial risk classification to ensure ascertainment of new-
borns who fall ill later on.5,12,30 The optimal frequency and
duration of observation needed to reliably detect such EOS
cases remain uncertain.42 We found that 88.6% of newborns
who developed signs of illness after birth did so within
24 hours and 98.0% within 48 hours after birth (Figure 3),
indicating that EOS cases not immediately allocated
antibiotic therapy are likely to present within a reasonable
timeframe, at which point treatment can be started. It is
not possible to determine how many of the 24 persistently
asymptomatic newborns with EOS would have developed
signs of illness and thereby qualified for treatment had they
gone without early empiric treatment; such instances could
modestly increase the proportion of EOS cases identified as
at risk or recommended treatment by the EOS Calculator.
Recommendations for blood cultures without antibiotic
treatment did not lead to the identification of any EOS
case. Among 1259 such cultures reported in the postimple-
mentation experience, only a single case—excluded from82our analysis as transient bacteremia—yielded a positive
result.12 This practice seems to have a very low yield.
Although not primary outcomes for this analysis, major
short-term morbidity or mortality were described in 3
included studies.12,34,37 Of the 118 EOS cases in those reports,
all 3 infants who died and one who survived but required
extracorporeal membrane oxygenation, were clinically ill at
birth, so there were no reported instances of harm resulting
from waiting for clinical signs to develop.12,34,37 These poten-
tially reassuring findings await confirmation by additional
experience.
The strengths of this analysis include a comprehensive sys-
tematic search including conference proceedings and abstract
databases, selective inclusion of representative birth cohorts,
and rigorous collection and analysis of individual patient
data with recalculation of the EOS Calculator results using
consistent methodology. A prior meta-analysis focused on
1-sided disagreement between national guidelines and the
EOS Calculator, included nonrepresentative cohorts, and
used variable population incidence rates.43
Some limitations should be considered when interpreting
these data. Themajority of data were collected retrospectively
or without actual EOS Calculator implementation, rendering
the analysis for those cases hypothetical. Limiting our anal-
ysis to prospective data did not alter the results, but larger da-
tasets are needed for confirmation. These data are aggregated
from a diverse array of clinical settings and countries, and
EOS Calculator performance may depend heavily on local
circumstances. Our analysis is based on the arbitrary risk
thresholds proposed by the EOS Calculator developers.
Different thresholds would lead to different proportions of
EOS cases being identified (Table VII). Potential
contaminant cultures (eg, coagulase-negative
Staphylococcus) were excluded from this analysis only if
considered nonpathogenic by the original authors; a stricter
exclusion of (potentially) spurious cases may increase the
proportion of EOS cases identified as at risk or
recommended treatment by the EOS Calculator. Finally,
the available data are limited to results in subjects
ultimately determined to have the disease in question, and
corresponding risk estimates for the disease-free remainder
of the population are not available, precluding robust
methods. This analysis therefore is essentially observational
in nature.
The EOS Calculator is increasingly being adopted and
endorsed by professional societies. Our findings carry some
important implications for clinical practice. First, when
considering adoption of the EOS Calculator, clinicians and
policy makers should evaluate the (expected) allocation of
EOS to categories, and relate this to the (expected) reduction
in empiric antibiotics. If, as our meta-analysis demonstrates,
almost 41% of EOS cases are initially categorized as low risk,
clinicians should be aware of this, and be cautious of a false
sense of security.
Second, the EOS Calculator workflows should include at
least 24 hours of clinical observation, because the vastAchten et al
July 2021 ORIGINAL ARTICLESmajority of EOS cases present within this timeframe. Because
a substantial portion of EOS cases occur in low-risk, well-
appearing infants, clinical vigilance should be universal,
regardless of individual estimated risks. Whether this
requires in-hospital observation or can be achieved with early
discharge or home births with parent instruction and/or
observation by healthcare providers at home may depend
heavily on local circumstances and healthcare system organi-
zation; this factor requires further study.
Third, because 84% of the EOS cases assigned to receive
antibiotics at initial assessment were already clinically ill,
the recommendation of antibiotics by the EOS Calculator
seems to lean heavily on signs of clinical illness. This finding
suggests that the EOS Calculator paradigm is akin to ap-
proaches primarily dependent on physical examination,
such as serial physical examinations.35,44,45
Finally, the EOS Calculator should be evaluated in the
context of alternative approaches, be they more categorical
(such as guidelines from the Centers for Disease Control and
Prevention46 or the National Institute for Health and Care
Excellence47), or more focused on clinical signs (such as serial
examinations).35,44,45 Relevant data collected byGoel et al indi-
cate that National Institute for Health and Care Excellence
guidelines lead to 4-fold greater us of empiric antibiotics
compared with the EOS Calculator, whereas antibiotics were
started immediately in 3 of 6 EOS cases according to either
strategy.33 Strategies based on serial examinations (or frequent
vital signs) have been found to reduce diagnostic testing and
antibiotic use,35,44,45 but prospective comparisons with
calculator-based strategies in clinical practice are lacking. We
recommend more comparisons between the EOS Calculator
and alternative approaches, with detailed clinical follow-up,
including re-admissions for sepsis.
In conclusion, in this large-scale individual patient meta-
analysis from EOS cases derived from birth cohorts of new-
borns 34 or more weeks of gestation, the EOS Calculator
application resulted in initial assignments to administration
or strong consideration of empiric antibiotics for 40.6%,
more frequent vital signs for 15.4%, and routine care for
44.0% of EOS cases. By 12 hours of age, these proportions
change to 61.1%, 11.1%, and 27.8%, respectively. Most new-
borns with EOS presented with signs of illness within
24 hours after birth. Decisions regarding implementation
of the EOS Calculator should consider these proportions in
the context of local circumstances. Clinical vigilance remains
essential for all newborns. Future studies should compare
multiple strategies and involve careful monitoring and
follow-up. n
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E coli 403/7 36.8 Negative 51.1 None or <2 h Well 0.11 — Not done 37.6
GBS 370/7 36.7 Positive 0 None or <2 h Well 0.04 — Not done 33.2
E coli 382/7 38.6 Negative 11.7 None or <2 h Well 0.99 — Not done 40
GBS 372/7 37.2 Positive 22.8 None or <2 h Well 0.36 — Not done 30.3
GBS 370/7 36.3 Negative 9.7 None or <2 h Well 0.04 — Not done 25.4
K pneumoniae 405/7 36.8 Negative 17.9 None or <2 h Well 0.07 20 Negative 49.1
E coli 390/7 37.6 Negative 13.2 None or <2 h Equivocal 2.38 — Negative 26.8
GBS 412/7 39.1 Positive 12.9 None or <2 h Well 4.58 — Negative 27.5
E coli 403/7 38.0 Negative 7.1 None or <2 h Well 0.30 36 Negative 101
GBS, group B Streptococcus; ROM, rupture of membranes.
Figure 3. Age at onset of clinical signs in EOS, by estimated
risk within 12 hours after birth. Data for 180 cases for which
ages at onset are known. (—: Infants who did not develop
signs of illness.)
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Other 403/7 36.3 Unknown 0 None or <2 h Well Well NR 0.01 0.01 Routine Routine
E coli 412/7 36.4 Negative 0 None or <2 h Well Ill 3 0.01 0.50 Routine Strongly
GBS 385/7 35.7 Unknown 10 None or <2 h Well Ill 3 0.01 0.50 Routine Strongly
GBS 394/7 36.7 Unknown 0 None or <2 h Well Ill 11 0.01 0.63 Routine Strongly
CoNS 391/7 36.7 Unknown 7 GBS abx >2 h Well Well NR 0.01 0.01 Routine Routine
Bacillus spp, CoNS 386/7 36.5 Negative 1.43 None or <2 h Well Well 50 0.02 0.02 Routine Routine
E coli 375/7 37.1 Unknown 1 GBS abx >2 h Well Well NR 0.02 0.02 Routine Routine
L monocytogenes 390/7 37.0 Unknown 0 None or <2 h Well Well 16 0.02 0.02 Frequent VS Routine
GBS 410/7 36.2 Negative 7 None or <2 h Well Well 1 0.02 0.02 Routine Routine
Enterococcus spp 400/7 36.2 Negative 12.2 None or <2 h Well Well 48 0.02 0.02 Routine Routine
GBS 416/7 36.1 Unknown 6 None or <2 h Well Ill 9 0.02 1.18 Frequent VS Strongly
GBS 402/7 36.8 Unknown 1.6 None or <2 h Well Ill 6 0.03 1.53 Frequent VS Strongly
GBS 393/7 36.6 Negative 6 None or <2 h Well Ill 5 0.03 1.53 Frequent VS Strongly
L monocytogenes 360/7 36.6 Unknown 0 None or <2 h Well Well 15 0.03 0.03 Frequent VS Routine
GBS 403/7 36.7 Unknown 4 None or <2 h Well Ill 7 0.03 1.75 Frequent VS Strongly
GBS 390/7 37.0 Positive 0 None or <2 h Well Well 14.5 0.03 0.03 Frequent VS Routine
GBS 390/7 36.6 Unknown 8 None or <2 h Well Ill 7 0.04 1.81 Frequent VS Strongly
GBS 405/7 36.9 Unknown 1.8 None or <2 h Well Ill 10 0.04 1.98 Frequent VS Strongly
GBS 395/7 36.8 Unknown 5 None or <2 h Well Ill 7 0.04 2.06 Frequent VS Strongly
VGS 385/7 36.7 Unknown 8.0 None or <2 h Well Well 14 0.04 0.04 Frequent VS Routine
CoNS 392/7 37.0 Negative 3 None or <2 h Well Well NR 0.04 0.04 Routine Routine
GBS 390/7 36.9 Negative 5 None or <2 h Well Ill 12 0.05 2.35 Frequent VS Strongly
GBS 381/7 36.0 Unknown 79 None or <2 h Well Ill 7 0.05 2.41 Frequent VS Strongly
GBS 384/7 36.8 Unknown 7 None or <2 h Well Well 22 0.05 0.05 Frequent VS Routine
Other 364/7 36.8 Negative 1 None or <2 h Well Well NR 0.05 0.05 Routine Routine
GBS 373/7 37.0 Unknown 1 None or <2 h Well Well — 0.05 0.05 Routine Routine
GBS 413/7 36.7 Negative 8.3 None or <2 h Well Ill 9 0.05 2.76 Frequent VS Strongly
E coli 406/7 36.7 Unknown 12 None or <2 h Well Ill 1 0.05 2.83 Frequent VS Strongly
GBS 374/7 36.8 Unknown 5 None or <2 h Well Ill 1 0.06 2.86 Frequent VS Strongly
GBS 394/7 37.0 Unknown 5.5 None or <2 h Well Well 36 0.06 0.06 Routine Routine
Enterococcus spp 395/7 37.0 Unknown 6 None or <2 h Well Well 37 0.06 0.06 Routine Routine
GBS 404/7 36.7 Negative 19 None or <2 h Well Well — 0.06 0.06 Routine Routine
GBS 380/7 37.0 Unknown 4 None or <2 h Well Well 52 0.06 0.06 Routine Routine
GBS 390/7 37.2 Negative 3 None or <2 h Well Ill 5 0.06 3.19 Frequent VS Treat
Other 390/7 37.3 Negative 2 None or <2 h Well Well NR 0.06 3.31 Routine Routine
GBS 391/7 37.2 Negative 3.5 None or <2 h Well Ill 6 0.06 0.06 Frequent VS Treat
Moraxella 382/7 36.6 Positive 8 None or <2 h Well Ill 12 0.07 3.45 Frequent VS Treat
GBS 380/7 36.9 Unknown 9 None or <2 h Well Ill 12 0.07 3.62 Frequent VS Treat
GBS 415/7 36.9 Unknown 5 None or <2 h Well Well 24 0.07 0.07 Frequent VS Routine
E coli 393/7 36.8 Negative 28 None or <2 h Well Well NR 0.08 3.80 Routine Routine
S aureus 406/7 36.6 Negative 36 None or <2 h Well Ill 6 0.07 3.85 Frequent VS Treat
GBS 366/7 36.7 Unknown 8 None or <2 h Well Ill 6 0.07 3.87 Frequent VS Treat
GBS 386/7 36.9 Unknown 16 None or <2 h Well Ill 8 0.08 0.08 Frequent VS Treat
GBS 402/7 36.8 Unknown 23 None or <2 h Well Ill 6 0.08 0.08 Frequent VS Treat
GBS 420/7 36.8 Unknown 7 None or <2 h Well Ill 11 0.08 3.93 Frequent VS Treat
Other 392/7 37.2 Negative 6 None or <2 h Well Well NR 0.08 3.94 Routine Routine
GBS 386/7 36.7 Unknown 36 None or <2 h Well Ill 5 0.08 4.11 Frequent VS Treat


















































































GBS 364/7 36.8 Unknown 5 None or <2 h Well Well 36 0.09 0.09 Routine Routine
GBS 386/7 37.0 Unknown 16 None or <2 h Well Well 36 0.09 0.09 Routine Routine
GBS 410/7 37.1 Positive 27 Broad abx 2-4 h Well Well — 0.09 0.09 Routine Routine
E coli 412/7 38.0 Unknown 3.1 GBS abx >2 h Well Ill 10 0.10 5.27 Frequent VS Treat
GBS 380/7 37.2 Unknown 8 None or <2 h Well Well 16 0.11 0.11 Frequent VS Routine
CoNS 384/7 37.2 Negative 13 None or <2 h Well Well NR 0.11 0.11 Routine Routine
S aureus 356/7 37.1 Unknown 17 GBS abx >2 h Well Well NR 0.12 0.12 Routine Routine
CoNS 392/7 37.5 Negative 6 None or <2 h Well Well NR 0.12 0.12 Routine Routine
GBS 400/7 37.4 Unknown 8.8 None or <2 h Well Well — 0.13 0.13 Routine Routine
GBS 372/7 37.1 Unknown 12 None or <2 h Well Ill 12 0.14 6.97 Frequent VS Treat
GBS 400/7 37.4 Positive 50 Broad abx ³4 h Well Well — 0.14 0.14 Routine Routine
E coli 386/7 37.8 Positive 9.5 GBS abx >2 h Well Ill 12 0.15 7.61 Frequent VS Treat
GBS 373/7 37.2 Negative 14.8 None or <2 h Well Well 36 0.16 0.15 Routine Routine
Other 380/7 36.6 Negative 0 None or <2 h Equivocal Equivocal NR 0.15 0.16 Routine Routine
VGS 411/7 37.7 Negative 2.4 None or <2 h Well Well 40 0.16 0.16 Routine Routine
GBS 375/7 37.2 Unknown 17 None or <2 h Well Well 64 0.16 0.16 Routine Routine
E coli 375/7 37.4 Unknown 8 None or <2 h Well Ill 12 0.16 8.20 Frequent VS Treat
CoNS 411/7 38.0 Negative 14 Broad abx 2-4 h Well Well NR 0.16 0.16 Routine Routine
GBS 384/7 37.4 Unknown 16 None or <2 h Well Well 25 0.17 0.17 Routine Routine
GBS 384/7 37.8 Unknown 3 None or <2 h Well Equivocal 5 0.17 2.12 Frequent VS Blood culture
GBS 374/7 37.1 Negative 33 None or <2 h Well Well 24 0.18 0.18 Frequent VS Routine
CoNS 401/7 36.5 Negative 1 None or <2 h Equivocal Equivocal 21 0.19 0.19 Routine Routine
GBS 402/7 37.4 Unknown 22 None or <2 h Well Well 14 0.19 0.19 Frequent VS Routine
GBS 360/7 36.6 Unknown 36 None or <2 h Well Well — 0.20 0.20 Routine Routine
GBS 410/7 37.3 Negative 27.6 None or <2 h Well Ill 3 0.20 10.23 Frequent VS Treat
E coli 355/7 36.8 Unknown 14 None or <2 h Well Well 26 0.21 0.21 Routine Routine
GBS 413/7 37.5 Unknown 10 None or <2 h Well Well — 0.21 0.21 Routine Routine
Other 384/7 36.9 Unknown 0 None or <2 h Equivocal Equivocal NR 0.22 11.13 Routine Routine
GBS 375/7 37.2 Unknown 34 None or <2 h Well Ill 6 0.22 0.22 Frequent VS Treat
VGS 410/7 38.3 Negative 11.5 Broad abx 2-4 h Well Well — 0.23 0.22 Routine Routine
Other 373/7 37.2 Unknown 29 None or <2 h Well Well NR 0.22 0.23 Routine Routine
Other 405/7 39.3 Negative 0 GBS abx >2 h Well Well NR 0.27 0.27 Routine Routine
VGS 413/7 37.4 Negative 29.1 None or <2 h Well Well — 0.27 0.27 Routine Routine
GBS 405/7 37.3 Negative 59 None or <2 h Well Well — 0.28 0.28 Routine Routine
GBS 402/7 36.7 Unknown 2 None or <2 h Equivocal Ill 3 0.33 1.40 Frequent VS Strongly
E coli 410/7 38.3 Unknown 25 Broad abx 2-4 h Well Well — 0.33 0.33 Routine Routine
GBS 390/7 38.3 Positive 0.2 None or <2 h Well Well — 0.34 0.34 Routine Routine
E coli 414/7 38.2 Negative 1.4 None or <2 h Well Well — 0.34 0.34 Routine Routine
E coli 400/7 36.3 Unknown 0 None or <2 h Ill Ill 0 0.35 0.35 Strongly Strongly
GBS 392/7 37.9 Positive 49 GBS abx >2 h Well Well — 0.35 0.35 Routine Routine
GBS 383/7 37.9 Negative 14.7 None or <2 h Well Ill 4.5 0.35 17.96 Frequent VS Treat
Other 376/7 36.5 Unknown 4 None or <2 h Equivocal Equivocal NR 0.36 0.36 Routine Routine
CoNS 395/7 37.9 Unknown 20 None or <2 h Well Well NR 0.38 0.38 Routine Routine
GBS 400/7 38.3 Positive 0.4 None or <2 h Well Well 24 0.38 0.38 Routine Routine
E coli 376/7 38.1 Positive 22 GBS abx >2 h Well Well NR 0.41 0.41 Routine Enhanced
GBS 401/7 38.3 Positive 1 None or <2 h Well Well 15 0.46 0.46 Frequent VS Enhanced
E coli 403/7 38.1 Negative 16 None or <2 h Well Well NR 0.48 0.48 Routine Enhanced

















































































































































VGS 410/7 38.8 Unknown 15 Broad abx ³4 h Well Well — 0.51 0.51 Routine Enhanced
E faecalis 416/7 37.9 Negative 16 None or <2 h Well Well NR 0.53 0.53 Routine Enhanced
GBS 385/7 37.9 Unknown 38 None or <2 h Well Well — 0.55 0.55 Routine Enhanced
S aureus 405/7 38.4 Negative 7 None or <2 h Well Well NR 0.59 2.49 Routine Enhanced
GBS 386/7 36.9 Unknown 5 None or <2 h Equivocal Ill 2 0.59 0.59 Frequent VS Strongly
VGS 382/7 36.8 Negative 7.1 None or <2 h Equivocal Equivocal 24.5 0.60 0.59 Routine Routine
Other 344/7 37.1 Unknown 65 GBS abx >2 h Well Well NR 0.59 0.60 Routine Enhanced
E faecalis 385/7 36.5 Unknown 25 None or <2 h Equivocal Equivocal NR 0.61 0.61 Routine Routine
GBS 383/7 36.8 Negative 8.9 None or <2 h Equivocal Equivocal 33.9 0.63 0.63 Routine Routine
Other 374/7 36.8 Negative 6 None or <2 h Equivocal Equivocal NR 0.69 0.69 Routine Routine
Enterococcus spp 370/7 36.6 Negative 8.1 None or <2 h Equivocal Equivocal — 0.70 0.70 Routine Routine
GBS 373/7 36.5 Negative 19 None or <2 h Equivocal Ill 3 0.71 3.02 Frequent VS Treat
GBS 382/7 38.2 Unknown 22 None or <2 h Well Well — 0.72 0.72 Routine Enhanced
GBS 380/7 37.1 Negative 3.1 None or <2 h Equivocal Equivocal 27.6 0.78 0.78 Routine Routine
E coli 365/7 37.2 Unknown 14 Broad abx ³4 h Equivocal Equivocal NR 0.81 0.81 Routine Routine
Other 385/7 37.1 Negative 6 None or <2 h Equivocal Equivocal NR 0.84 0.84 Routine Routine
S aureus 423/7 38.3 Unknown 59 Broad abx 2-4 h Well Well — 0.89 0.89 Routine Enhanced
GBS 373/7 36.7 Negative 17.1 None or <2 h Equivocal Ill 6.9 0.93 3.94 Frequent VS Treat
S aureus 405/7 37.0 Negative 13 None or <2 h Equivocal Equivocal NR 1.02 1.02 Blood culture Blood culture
Other 372/7 37.0 Negative 6 None or <2 h Equivocal Equivocal NR 1.05 1.05 Blood culture Blood culture
GBS 356/7 37.0 Positive 83 None or <2 h Well Well 33 1.07 1.07 Blood culture Blood culture
GBS 391/7 37.2 Unknown 8 None or <2 h Equivocal Ill 3 1.08 4.57 Blood culture Treat
GBS 404/7 37.0 Unknown 15 None or <2 h Equivocal Ill 1 1.10 4.65 Blood culture Treat
GBS 422/7 38.5 Unknown 63 GBS abx >2 h Well Well — 1.18 1.18 Blood culture Blood culture
GBS 393/7 37.1 Negative 17.68 None or <2 h Equivocal Ill 4 1.20 5.08 Blood culture Treat
E coli 395/7 38.9 Negative 9 None or <2 h Well Well NR 1.25 5.20 Blood culture Blood culture
GBS 384/7 37.1 Unknown 14 None or <2 h Equivocal Ill 10 1.23 1.25 Blood culture Treat
Other 370/7 36.8 Unknown 0 None or <2 h Ill Ill NR 1.29 1.29 Strongly Strongly
CoNS 344/7 36.9 Unknown 2 GBS abx >2 h Equivocal Equivocal NR 1.29 1.29 Blood culture Blood culture
VGS 366/7 36.8 Negative 0 None or <2 h Ill Ill 0 1.32 1.32 Strongly Strongly
E coli 390/7 39.5 Unknown 14.0 GBS abx >2 h Well Ill 12 1.42 68.62 Blood culture Treat
GBS 396/7 39.0 Positive 27 Broad abx 2-4 h Well Well — 1.46 1.46 Blood culture Blood culture
GBS 410/7 37.3 Negative 9 None or <2 h Equivocal Ill 3 1.51 6.38 Blood culture Treat
GBS 395/7 37.5 Negative 7.37 None or <2 h Equivocal Ill 8 1.59 6.71 Blood culture Treat
E coli 400/7 39.0 Negative 12.3 None or <2 h Well Well — 1.68 1.68 Blood culture Blood culture
GBS 401/7 37.4 Negative 6 Broad abx ³4 h Ill Ill 0 1.69 1.69 Strongly Strongly
Other 390/7 36.7 Negative 5 None or <2 h Ill Ill NR 1.72 1.72 Strongly Strongly
CoNS 401/7 36.8 Positive 13.78 GBS abx >2 h Ill Ill 0 1.85 1.85 Strongly Strongly
L monocytogenes 353/7 39.2 Unknown 1.7 GBS abx >2 h Well Well — 1.86 1.86 Blood culture Blood culture
Other 370/7 36.6 Negative 2 None or <2 h Ill Ill NR 1.90 1.90 Strongly Strongly
GBS 420/7 37.0 Unknown 20 None or <2 h Equivocal Ill 1 1.94 8.17 Blood culture Treat
VGS 401/7 37.4 Unknown 0 None or <2 h Ill Ill 0 1.95 1.95 Strongly Strongly
GBS 342/7 37.0 Unknown 72 None or <2 h Well Well — 1.97 1.97 Blood culture Blood culture
GBS 363/7 37.2 Negative 5.3 None or <2 h Equivocal Ill 7.3 2.04 8.61 Blood culture Treat
E coli 364/7 37.2 Negative 10 None or <2 h Equivocal Equivocal NR 2.39 9.75 Blood culture Blood culture
GBS 360/7 37.0 Unknown 8 None or <2 h Equivocal Ill 3 2.32 2.33 Blood culture Treat
GBS 395/7 37.0 Negative 3.18 None or <2 h Ill Ill 0 2.33 2.37 Strongly Strongly


















































































GBS 402/7 37.0 Unknown 84 None or <2 h Equivocal Ill 1 2.50 10.51 Blood culture Treat
Other 370/7 39.1 Negative 7 None or <2 h Well Well NR 2.71 2.71 Blood culture Blood culture
Other 365/7 37.6 Negative 3 None or <2 h Equivocal Equivocal NR 2.75 2.75 Blood culture Blood culture
VGS 401/7 37.8 Negative 9.5 None or <2 h Equivocal Equivocal NR 2.87 2.87 Blood culture Blood culture
E coli 361/7 37.3 Unknown 58.08 GBS abx >2 h Equivocal Equivocal 5 2.94 2.94 Blood culture Blood culture
GBS 395/7 36.9 Negative 10 None or <2 h Ill Ill NR 2.96 2.96 Strongly Strongly
GBS 422/7 37.3 Unknown 14 None or <2 h Equivocal Equivocal — 3.03 3.03 Treat Treat
GBS 394/7 37.8 Negative 13 None or <2 h Equivocal Ill 6 3.15 13.21 Treat Treat
E coli 400/7 39.4 Negative 14 None or <2 h Well Well 10 3.31 3.31 Treat Treat
GBS 386/7 36.8 Unknown 16 None or <2 h Ill Ill 0 3.31 3.31 Treat Treat
GBS 402/7 37.6 Unknown 26 None or <2 h Equivocal Ill 3 3.43 14.37 Treat Treat
Bacillus spp 371/7 37.0 Unknown 2 None or <2 h Ill Ill 0 3.48 3.48 Treat Treat
E coli 392/7 37.5 Unknown 18.8 GBS abx >2 h Ill Ill 0 3.59 3.59 Treat Treat
GBS 414/7 36.7 Negative 15.2 None or <2 h Ill Ill 0 3.68 3.68 Treat Treat
GBS 363/7 37.2 Negative 24.2 None or <2 h Equivocal Equivocal — 3.74 3.74 Treat Treat
GBS 384/7 37.1 Unknown 6 None or <2 h Ill Ill 0 3.77 3.77 Treat Treat
GBS 410/7 37.4 Unknown 1 None or <2 h Ill Ill 0 4.01 4.01 Treat Treat
GBS 402/7 37.1 Negative 9 None or <2 h Ill Ill NR 4.07 4.07 Treat Treat
Oral flora 393/7 37.0 Negative 15.75 None or <2 h Ill Ill 0 4.14 4.14 Treat Treat
GBS 380/7 39.3 Negative 25.5 None or <2 h Well Ill 6 4.42 4.31 Treat Treat
VGS 385/7 39.5 Negative 16.6 None or <2 h Well Well 12 4.31 4.35 Treat Treat
GBS 404/7 37.0 Unknown 12.75 None or <2 h Ill Ill 0 4.35 186.69 Treat Treat
GBS 405/7 37.3 Unknown 3.5 None or <2 h Ill Ill 0 4.50 4.50 Treat Treat
GBS 413/7 36.9 Unknown 12 None or <2 h Ill Ill 0 4.54 4.51 Treat Treat
VGS 382/7 37.0 Negative 14.25 None or <2 h Ill Ill 0 4.53 4.51 Treat Treat
L monocytogenes 396/7 37.1 Negative 13 None or <2 h Ill Ill NR 4.51 4.53 Treat Treat
L monocytogenes 396/7 37.1 Negative 13 None or <2 h Ill Ill NR 4.51 4.54 Treat Treat
GBS 370/7 37.7 Unknown 11 None or <2 h Equivocal Ill 5 4.59 19.16 Treat Treat
GBS 410/7 37.1 Unknown 10 None or <2 h Ill Ill 0 5.08 5.08 Treat Treat
E coli 361/7 37.0 Negative 1.83 None or <2 h Ill Ill 0 5.39 5.38 Treat Treat
Group G Streptococcus 396/7 36.9 Negative 40.98 None or <2 h Ill Ill 0 5.58 5.39 Treat Treat
E coli 401/7 39.3 Negative 53 None or <2 h Well Well — 5.38 5.58 Treat Treat
Not specified 376/7 37.0 Negative 21 None or <2 h Ill Ill 0 5.97 5.97 Treat Treat
GBS 381/7 37.1 Unknown 16 None or <2 h Ill Ill NR 6.00 5.98 Treat Treat
GBS 402/7 37.2 Negative 16 None or <2 h Ill Ill 0 5.98 6.00 Treat Treat
GBS 370/7 37.0 Negative 12 None or <2 h Ill Ill NR 6.45 6.45 Treat Treat
VGS 414/7 37.1 Unknown 12 None or <2 h Ill Ill 0 6.50 6.50 Treat Treat
E coli 414/7 39.7 Negative 10.5 None or <2 h Well Well — 6.63 6.63 Treat Treat
GBS 421/7 39.4 Unknown 17 None or <2 h Well Well — 6.67 6.67 Treat Treat
GBS 383/7 36.8 Unknown 63 None or <2 h Ill Ill 0 6.90 6.78 Treat Treat
E coli 410/7 37.2 Unknown 14 None or <2 h Ill Ill NR 6.78 6.90 Treat Treat
GBS 372/7 37.2 Unknown 9 None or <2 h Ill Ill 0 7.28 7.28 Treat Treat
Other 395/7 37.3 Negative 22 None or <2 h Ill Ill NR 7.65 7.53 Treat Treat
E coli 414/7 37.2 Negative 13.1 None or <2 h Ill Ill 0 7.53 7.59 Treat Treat
VGS 403/7 37.0 Unknown 45 None or <2 h Ill Ill 0 7.59 7.64 Treat Treat
GBS + E coli 406/7 37.3 Negative 15.45 None or <2 h Ill Ill 0 7.64 7.65 Treat Treat
Other 410/7 37.4 Unknown 9 None or <2 h Ill Ill NR 7.77 7.71 Treat Treat

















































































































































CoNS 382/7 37.4 Negative 13 None or <2 h Ill Ill NR 8.12 8.12 Treat Treat
GBS 380/7 36.9 Unknown 60 None or <2 h Ill Ill 0 8.65 8.65 Treat Treat
VGS 364/7 37.2 Negative 6.8 None or <2 h Ill Ill 0 8.72 8.72 Treat Treat
GBS 373/7 37.1 Unknown 23 None or <2 h Ill Ill NR 8.72 8.72 Treat Treat
VGS 353/7 37.5 Unknown 0 None or <2 h Ill Ill 0 9.52 9.52 Treat Treat
GBS 351/7 36.8 Unknown 45 GBS abx >2 h Ill Ill 0 9.75 9.75 Treat Treat
GBS 421/7 37.2 Unknown 13 None or <2 h Ill Ill 0 9.87 9.87 Treat Treat
GBS 376/7 37.5 Unknown 10 None or <2 h Ill Ill NR 9.94 9.94 Treat Treat
E coli 361/7 37.1 Negative 8.6 None or <2 h Ill Ill 0 10.31 10.31 Treat Treat
CoNS 341/7 37.0 Negative 0 None or <2 h Ill Ill NR 12.17 12.17 Treat Treat
VGS 350/7 37.0 Unknown 2 None or <2 h Ill Ill 0 12.62 12.62 Treat Treat
VGS 385/7 37.6 Negative 22.6 None or <2 h Ill Ill 0 13.01 13.01 Treat Treat
E coli 386/7 37.6 Negative 25 None or <2 h Ill Ill 0 13.36 13.36 Treat Treat
Enterococcus spp 410/7 37.8 Unknown 8 None or <2 h Ill Ill 0 13.81 13.81 Treat Treat
E coli 381/7 38.1 Negative 2.5 None or <2 h Ill Ill 0 14.10 14.10 Treat Treat
GBS 362/7 37.3 Unknown 12 None or <2 h Ill Ill 0 15.26 15.26 Treat Treat
E coli 416/7 37.5 Negative 18.2 None or <2 h Ill Ill 0 15.34 15.34 Treat Treat
Not specified 390/7 38.0 Negative 12 None or <2 h Ill Ill 0 17.82 17.82 Treat Treat
GBS 375/7 37.2 Unknown 89 None or <2 h Ill Ill 0 18.70 18.70 Treat Treat
GBS 400/7 38.3 Unknown 50 GBS abx >2 h Ill Ill 0 20.10 20.10 Treat Treat
GBS 354/7 37.0 Negative 27 None or <2 h Ill Ill 0 20.41 20.41 Treat Treat
E coli 411/7 39.1 Positive 17.1 GBS abx >2 h Equivocal Equivocal — 20.74 20.74 Treat Treat
Enterococcus spp 391/7 38.7 Negative 25.5 Broad abx ³4 h Ill Ill 0 22.18 22.18 Treat Treat
GBS 371/7 38.9 Negative 8 None or <2 h Equivocal Equivocal NR 23.44 23.36 Treat Treat
GBS 416/7 37.8 Unknown 15 None or <2 h Ill Ill 0 23.36 23.44 Treat Treat
H influenzae 402/7 38.5 Unknown 62 Broad abx 2-4 h Ill Ill 0 31.53 31.53 Treat Treat
CoNS 394/7 39.4 Negative 11 None or <2 h Equivocal Equivocal NR 34.72 34.72 Treat Treat
H influenzae 383/7 39.4 Negative 9 None or <2 h Equivocal Equivocal — 35.64 35.64 Treat Treat
Not specified 414/7 38.2 Unknown 16 None or <2 h Ill Ill 0 39.46 37.15 Treat Treat
E coli 404/7 38.8 Negative 39.1 Broad abx 2-4 h Ill Ill 0 39.14 39.14 Treat Treat
Enterococcus spp 403/7 38.3 Negative 21 None or <2 h Ill Ill 0 37.15 39.46 Treat Treat
GBS 400/7 39.0 Unknown 24 Broad abx 2-4 h Ill Ill 0 40.76 40.76 Treat Treat
E coli 373/7 39.0 Negative 18 Broad abx ³4 h Ill Ill 0 42.98 42.98 Treat Treat
GBS 391/7 39.3 Negative 16 GBS abx >2 h Ill Ill 0 51.21 51.21 Treat Treat
GBS 390/7 39.5 Positive 2.78 GBS abx >2 h Ill Ill 0 66.31 66.31 Treat Treat
Pneumococcus 384/7 38.9 Negative 15.8 None or <2 h Ill Ill 0 80.62 80.62 Treat Treat
Not specified 392/7 39.3 Negative 14 None or <2 h Ill Ill 0 126.23 126.23 Treat Treat
E coli 400/7 39.3 Negative 16.6 None or <2 h Ill Ill 0 136.13 136.13 Treat Treat
Other 403/7 39.4 Negative 17 None or <2 h Ill Ill NR 163.94 163.94 Treat Treat
E coli 403/7 39.3 Negative 162.7 Broad abx 2-4 h Ill Ill 0 167.71 167.71 Treat Treat
Not specified 341/7 37.2 Negative 197 None or <2 h Ill Ill 0 225.89 225.89 Treat Treat
Not specified 341/7 37.3 Positive 322 None or <2 h Ill Ill 0 411.84 411.84 Treat Treat
abx, antibiotics; Blood culture, blood culture and frequent vital signs; CoNS, coagulase-negative staphylococcus; GBS, group B Streptococcus; NR, not reported for any subjects in source report; ROM, duration of ruptured membranes at birth; Strongly, strongly consider















































Table IV. Risk of bias assessments for included studies
Study Year Data source
Outcome Predictors
Missing data OverallDefinition Follow-up duration Blinding Definition Blinding
Achten et al25 2018 Unclear Low Unclear Low Unclear High Unclear Unclear
Arora et al26 2019 Unclear Low Low Low Low Unclear Unclear Low
Bajracharya et al27 2019 High High Low Low Low High Low High
Benaim et al28 2019 High High Low Low Low High High High
Davidson et al29 2016 Low High Unclear Low High High Low Unclear
Dhudasia et al30 2018 High Low Low Low Low High Low High
Fischer et al31 2018 High Low Low Low Low High Low High
Fowler et al32 2019 High High Low Low Low High Unclear High
Goel et al33 2020 High Low Low Low Low Low Low Low
Hershkovich-Shporen et al34 2019 High High Low Low Low High Unclear High
Joshi et al35 2019 High Low Low Low Low High Low High
Kopec et al36 2018 High Low Unclear Low Low High Low High
Kuzniewicz12 Low Low Low Low Low Unclear Low Low
Morris et al37 2017 High Low Low Low Low Unclear Unclear High
Perez et al38 2019 Low Low High Low Low Unclear Unclear Unclear
Procianoy et al39 2019 High High Low Low Unclear High Low High
Sharma et al40 2019 High High High Low Low High Unclear High
Strunk et al41 2018 Low High Low Low Low Low Low Low
ROM, rupture of membranes.
Data source: prospective low, combined unclear, retrospective or unknown: high.
Outcome definition: low if handling of contaminants explained, unclear if not explained.
Follow-up duration: low if <72 hours timeframe specified, unclear if not specified, high if other definition.
Outcome blinding: low for all, given blood culture results considered unlikely to be affected by bias as a lack of blinding.
Predictor definition: low if according to development studies, high if different from original development studies.
Predictor blinding: low if any blinding or prospective study, high if no blinding, unclear if not described.
Missing data: low if none, unclear if undescribed or imputed, high if missing data, inadequately imputed or excluded.
Overall: consensus judgment depending on severity of bias issues, emphasis on data source.
Table VI. Results of analysis restricted to prospectively
collected data
Recommendations n (%; 95% CI)
At initial assessment
Empiric treatment 25 (41.7; 29.1-55.1)
Strongly consider treatment 6 (10.0; 3.8-20.5)
Give or strongly consider treatment 31 (51.7; 38.4-64.8)
Blood culture and frequent vital signs 5 (8.3; 2.8-18.4)
Frequent vital signs 0 (0.0; 0.0-4.9)
Routine care 24 (40.0; 27.6-53.5)
Total 60 (100.0)
Within first 12 hours
Empiric treatment 36 (60.0; 46.5-72.4)
Strongly consider treatment 8 (13.3; 5.9-24.6)
Give or strongly consider treatment 44 (51.7; 38.4-64.8)
Blood culture and frequent vital signs 2 (3.3; 0.4-11.5)
Frequent vital signs 0 (0.0; 0.0-4.9)
Routine care 14 (23.3; 13.4-36.0)
Total 60 (100.0)
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Probability of recommendations at initial assessment (%) Probability of recommendations at by 12 hours of age (%)
All infants
Infants without
















0.45 4.0 60.3 (53.7-66.6) 60.7 (54.1-67.0) 40.3 (32.4-48.5) 79.1 (73.3-84.1) 79.5 (73.7-84.5) 47.3 (36.7-58.0)
0.90 2.0 51.7 (45.1-58.3) 52.1 (45.5-58.7) 27.3 (20.4-35.0) 70.5 (64.2-76.3) 72.6 (66.5-78.3) 29.7 (20.5-40.2)
1.80 1.0 42.7 (36.3-49.3) 45.3 (38.8-51.9) 16.9 (11.3-23.8) 61.5 (55.0-67.8) 69.2 (62.9-75.1) 20.9 (13.1-30.7)
2.00 0.9 40.6 (34.2-47.2) 44.0 (37.6-50.6) 14.9 (9.7-21.6) 59.0 (52.4-65.3) 68.4 (62.0-74.3) 18.7 (11.3-28.2)
2.25 0.8 40.2 (33.8-46.8) 43.6 (37.1-50.2) 14.3 (9.2-20.8) 57.3 (50.7-63.7) 67.9 (61.6-73.9) 17.6 (10.4-27.0)
2.57 0.7 37.6 (31.4-44.2) 41.9 (35.5-48.5) 11.7 (7.1-17.8) 53.8 (47.2-60.4) 67.1 (60.7-73.1) 15.4 (8.7-24.5)
3.00 0.6 35.9 (29.8-42.4) 40.6 (34.2-47.2) 9.7 (5.6-15.6) 50.9 (44.3-57.4) 65.8 (59.3-71.9) 12.1 (6.2-20.6)
3.60 0.5 32.9 (26.9-39.3) 38.9 (32.6-45.5) 7.1 (3.6-12.4) 47.0 (40.5-53.6) 65.0 (58.5-71.1) 9.9 (4.6-17.9)
4.50 0.4 29.1 (23.3-35.3) 37.6 (31.4-44.2) 5.2 (2.3-10.0) 39.7 (33.4-46.3) 64.1 (57.6-70.2) 7.7 (3.1-15.2)
6.00 0.3 24.4 (19.0-30.4) 36.8 (30.6-43.3) 3.9 (1.4-8.3) 32.9 (26.9-39.3) 63.7 (57.2-69.8) 6.6 (2.5-13.8)
9.00 0.2 16.2 (11.8-21.6) 35.9 (29.8-42.4) 2.6 (0.7-6.5) 21.8 (16.7-27.6) 62.8 (56.3-69.0) 4.4 (1.2-10.9)
18.00 0.1 10.3 (6.7-14.9) 35.9 (29.8-42.4) 2.6 (0.7-6.5) 12.0 (8.1-16.8) 62.8 (56.3-69.0) 4.4 (1.2-10.9)
Bold values represent treatment threshold and corresponding population EOS incidence used in main analysis.
*With low population incidence rates, effects of changes in treatment thresholds closely approximate effects of inverse changes in the population incidence rates stipulated in the Calculator. Results
presented for threshold values are based on a fixed population incidence of 0.6 per 1000, those for incidence rates on a fixed treatment threshold of 3 per 1000.
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